ExcepGen Inc
Biotechnology company utilizing its RNAx platform to develop advanced vaccines and therapeutics addressing viral infections linked to premature aging and shortened lifespan.
Notes
ExcepGen is a biotechnology company developing advanced vaccines and therapeutics using its proprietary RNAx platform. The company focuses on addressing viral infections that have been linked to premature aging and shortened lifespan, representing an intersection of infectious disease treatment and longevity research.
The company's approach recognizes the emerging understanding that certain chronic viral infections may contribute to aging processes and age-related diseases. By developing vaccines and therapeutics targeting these infections, ExcepGen aims to not only treat infections but potentially extend healthy lifespan.
ExcepGen has received funding from VitaDAO, a decentralized autonomous organization focused on funding longevity research.
Team
- Leadership team information not publicly disclosed
Additional Research Findings
- Proprietary RNAx platform
- Focus on vaccines and therapeutics
- Funded by VitaDAO
- Longevity research intersection
- Viral infection targets linked to aging
- Novel therapeutic approach
Sources
Investors
| Name | Location | Type | Stages | Portfolio |
|---|---|---|---|---|
| VitaDAO | Decentralized (Global) | dao | seed | 7 |